S100A12 Protein Levels in Juvenile Idiopathic Arthritis (JIA): a Systematic Review and Meta-Analysis
Insights
Serum S100A12 protein levels are significantly elevated in children with juvenile idiopathic arthritis (JIA) compared to healthy individuals. This finding suggests S100A12 may serve as a potential biomarker for diagnosing JIA.
Area of Science:
- Biochemistry
- Immunology
- Pediatrics
Background:
- Juvenile idiopathic arthritis (JIA) is a significant cause of childhood disability.
- Previous studies show inconsistent associations between S100A12 protein levels and JIA.
- Further investigation is needed to clarify the role of S100A12 in JIA.
Purpose of the Study:
- To systematically review and meta-analyze the association between S100A12 protein levels and JIA.
- To assess the diagnostic potential of S100A12 as a biomarker for JIA.
Main Methods:
- Systematic literature search of Embase, PubMed/Medline, Web of Science, and Scopus up to December 2022.
- Inclusion of 9 studies with 518 JIA patients and 345 healthy controls.
- Data analysis using R-4.4.0 software.
Main Results:
- Pooled analysis revealed significantly higher serum S100A12 protein levels in JIA patients versus healthy controls (SMD = 2.18).
- Subgroup analyses by geography (Europe, Asia) and study type (cohort, case-control) also showed significant increases in S100A12 levels.
- High heterogeneity was observed across subgroups, indicating variability in study findings.
Conclusions:
- Serum S100A12 protein concentrations are significantly elevated in JIA patients.
- S100A12 protein shows potential as a biomarker for juvenile idiopathic arthritis.
- Further research may refine the clinical utility of S100A12 in JIA diagnosis and management.
Background:
Juvenile idiopathic arthritis (JIA) is a childhood inflammatory disease, which is a common cause of disability among the younger population. S100A12 protein level is found to be associated with the patients of JIA; though, the findings on this are inconsistent. Therefore, we conducted a systematic review and meta-analysis to assess the association of S100A12 protein levels with juvenile idiopathic arthritis.
Methods:
Relevant published studies up to December 2022 were identified by systematic literature searching on Embase, PubMed/Medline, Web of Science, and Scopus for exploring the association of S100A12 protein levels with juvenile idiopathic arthritis (JIA). The data analysis was performed using the R-4.4.0 software.
Results:
We included 9 eligible studies on serum S100A12 protein levels in JIA and healthy controls, which encompassed 518 JIA patients and 345 healthy control subjects. The pooled analysis revealed that the serum S100A12 protein levels increased significantly (summary SMD = 2.18, 95% CI: 0.63 - 3.74, overall effect size z = 2.76, p < 0.01) in JIA subjects in comparison to healthy control subjects. The pooled results of subgroup analysis for the Europe and Asia group' studies were SMD = 2.75, (95% CI [-0.09 to 5.58]; p < 0.01) and SMD = 1.53, (95% CI [-0.27 to 3.32]; p < 0.01), respectively, and both groups based on geographical regions exhibited significant hetero-geneity (I2 = 97.0% and I2 = 98.0% respectively, p < 0.01). Similarly, in cohort and case-control study groups, the results were SMD = 1.70, (95% CI [0.36 to 3.04]; p < 0.01) and SMD = 1.29, (95% CI [0.03 to 2.55]; p < 0.01), respectively, and both groups based on study type also exhibited significant heterogeneity (I2 = 97.0% and I2 = 96.0%, respectively, p < 0.01).
Conclusions:
This meta-analysis suggests that the S100A12 protein serum concentrations of JIA were significantly higher than those of healthy controls, which suggests that serum S100A12 protein could be a potential biomarker for JIA.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...